Kornimate/medical-research-clean huggingface dataset:
a multi-surgery assessment of zynrelef (htx-011), amaze.

Conditions: Postoperative Pain; Total Shoulder Arthroplasty; Multimodal Analgesia

Summary: this is a phase 4, randomized, blinded, active-controlled, multicohort study to evaluate htx-011 compared with bupivacaine hcl in subjects undergoing total shoulder arthroplasty (tsa) (cohort 1).


Eligibility criteria:
inclusion criteria: * has american society of anesthesiologists (asa) physical status of i, ii, or iii. * is scheduled to undergo a unilateral total shoulder arthroplasty. exclusion criteria: * is undergoing a revision surgery. * has a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to bupivacaine (or other local anesthetics), nsaids, acetaminophen, oxycodone, morphine, or hydromorphone. * history of severe allergic reaction to aspirin or other nsaids, or known history of severe gastrointestinal adverse reactions associated with nsaid use. * has taken meloxicam within 10 days prior to the scheduled surgery, or any nsaid within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection. * opioid use for most days within the last 3 months prior to screening in the opinion of the investigator. * has been administered immediate-release bupivacaine hcl within 5 days prior to the scheduled surgery, or a modified-release bupivacaine product within 14 days prior to the scheduled surgery. * has initiated treatment with any of the following medications within 1 month prior to study drug administration: selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, or cyclooxygenase-2 inhibitors. * has been administered systemic steroids within 5 half-lives or 10 days prior to the scheduled surgery (whichever is longer). * has a known or suspected history of drug abuse, a positive drug screen (except for cannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5 years. * suspected or confirmed active coronavirus disease 2019 (covid-19) infection. * had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix. * has undergone 3 or more surgeries within 12 months, other than for diagnostic procedures (eg, colonoscopy). * has a body mass index (bmi) \>40 kg/m2.
evaluation of the renal function in an ultra-endurance race.

Conditions: Renal Insufficiency, Acute

Summary: during ultra endurance events, athletes experience extreme physical and mental demands, sometimes at the limits of the adaptive response to human physiology. this is particularly true for the renal function, and some evidence for acute renal failure has already been shown, sometimes leading to dialysis. however, the precise mechanisms involved in acute renal failure in such ultra endurance races are not clearly elucidated. the aim of our study is to estimate glomerular filtration rate from serum and urinary creatinine and cystitin c at the beginning and at the end of a 110 km ultra endurance race. our hypothesis is that during the ultra endurance race, renal function may be injured, with a risk for the athlete.


Eligibility criteria:
inclusion criteria: * age: at least 20 years old * athlete that is officially registered to the 110 km race (infernal trail des vosges) * athlete informed by a member (md) of the medical staff of the race. * athlete that gives and signes the informed consent to the research protocol exclusion criteria: * athlete with a known disease that needs the following medications: * medications influencing the renin-angiotensin-aldosteron system (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosteron receptor blockers) * diuretic drugs * anticoagulant drugs * non-steroidal anti-inflammatory drugs * athlete with a known thyroid disease (because of the influence on the serum cystatin level) * athlete with a know renal disease * athlete with a know inflammatory disease

Keywords: renal failure athlete ultra endurance
urodynamic evaluation in patients with anorectal malformation according to spinal cord abnormalities

Conditions: Anorectal Malformation

Summary: this study will examine the effects of spinal cord abnormalities on perioperative neurovesical dysfunction in patients with anorectal abnormalities.


Eligibility criteria:
inclusion criteria: * anorectal malformation patients who underwent preoperative and postoperative urodynamic studies exclusion criteria: * severe artifacts in urodynamic result graph when the postoperative urodynamic study was done after spinal surgery

Keywords: patients with anorectal malformation
gut microbiota and bile acids in type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2; Metformin; YH1

Summary: the investigators will evaluate the stool microbiota, serum and fecal bile acid composition, and changes in blood glucose and lipid profile before and after one month of metformin or yh1 treatment.


Eligibility criteria:
inclusion criteria: 1. treatment-naïve male patients with type 2 diabetes; 2. aged 20-65 years; 3. body mass index (bmi) ≥ 24 kg/m2; 4.7 % ≤ glycated hemoglobin (hba1c) \< 9 %; 5.low-density cholesterol (ldl-c) ≥ 130 mg/dl; 6.expected to receive metformin 500 mg tid or yh1 6g tid for one month exclusion criteria: 1. type 1,or other specific types of diabetes; 2. female; 3. history of oral hypoglycemic agents (ohas) treatment or insulin therapy; 4. use of lipid-lowering drugs within the past six months; 5. serious gastrointestinal (gi) tract diseases, including peptic ulcers and gi tract bleeding; 6. hepatic insufficiency with alt \>72 u/l or renal insufficiency with an egfr \< 60 ml/min/1.73 m2; 7. history of stressful situations, including diabetic ketoacidosis, nonketotic hyperosmolar diabetic coma, infectious disease, or surgery in the previous month; 8. mental illness; 9. current smoking status, alcohol or drug abuse; 10. hemoglobin disease or chronic anemia; 11. underlying conditions that could lead to poor compliance; 12. severe organic diseases, including cancer, coronary heart disease, myocardial infarction or cerebrovascular disease; 13. continuous antibiotic or probiotics use for over 3 days within 3 months prior to enrollment; 14. continuous use of weight loss drug for over 1 month; 15. history of yh1 therapy, or chinese medicine treatment within the past one month.

Keywords: bile acid microbiota
the prognosis of fetoscopy treatment of twin transfusion syndrome

Conditions: Twin Diseases

Summary: fetal medicine in china is still a new, young discipline, and the development is very rapid. after nearly 10 years of development, the clinical diagnosis and treatment guidelines of some complicated twin diseases has been established. among them, twin-to-twin-transfusion syndrome (ttts) is serious disease in twin pregnancy, and the factors affecting prognosis after fetoscopic laser surgery are part of the study. through this study, the investigators expect to achieve better prediction indicators of the prognosis of ttts.

a better guideline for twin-to-twin-transfusion syndrome are anticipated to be established in china. fetoscopic laser surgery is applied to treat ttts. after surgery, better prediction indicators of the prognosis of ttts are needed.

Eligibility criteria:
inclusion criteria: ttts after fetoscopic laser surgery. exclusion criteria: pregnant women who refuse to take part in the study

Keywords: ttts
study of electrical stimulation in pulmonary function in intensive care unit

Conditions: Respiratory Distress Syndrome, Adult

Summary: introduction: the mechanical ventilation (mv), a support method used in intensive care units (icu), reaches approximately 90% of critical patients whose withdrawal process represents 40% of the total time of their use. for this purpose transcutaneous electrical diaphragmatic stimulation (teds), which by means of electrodes placed in motor action points on the phrenic nerve tend to provide improvement of the diaphragm muscle function. objective: to analyze the effect of two protocols of transcutaneous electrical diaphragmatic stimulation on the ventilatory and cardiorespiratory parameters of critically ill patients. method: clinical, longitudinal, prospective, quantitative, single center trial will be performed with 30 (thirty) participants in invasive mechanical ventilatory support, randomly divided into three groups: experimental group 1 (ge-1; n = 10) where they will be submitted to the teds protocol; experimental group 2 (ge-2; n = 10), where they will be submitted to the teds protocol based on the studies of cancelliero et al. (2012); control group (gc; n = 10) where they will not be submitted to teds. all groups will receive physiotherapeutic care from the staff of the adult icu of the fhcgv. the interventions will consist of ten sessions of physical therapy in each participant in the afternoon shift, for ten consecutive days, 1 time a day. for the teds procedure, the orion tens ii (orion-sp-brazil) model will be used, the wright analogue respirometer (spire-sp-brazil) will be used for the minute volume evaluation (v'). the variables of systolic blood pressure (sbp), diastolic blood pressure (dbp), heart rate (hr) and peripheral oxygen saturation (spo2) will also be monitored in order to verify if the teds application interferes with the hemodynamic variables of these patients. the data collected will be linked to microsoft office excel® 2010 software and later transformed into tables and graphs. the information collected will be submitted to statistical analysis through the statistical package spss 22.0, applying the descriptive statistics for the characterization of the sample and then selecting the specific tests for the respective variances, adopting a level of significance of p≤0.05 for statistical inferences.


Eligibility criteria:
inclusion criteria: * individuals of both sexes aged 60 years and older up to 80 years, * in invasive mv for more than 48 hours, * with respiratory drive, * using mv in the mode of intermittent mandatory synchronized ventilation (vmis) or (vps), * connected to the orotracheal tube or via tracheostomy, * hemodynamically stable, * neuromuscular junction of the entire diaphragm, * absence of sedatives. exclusion criteria: * presence of pacemaker, hyperthermia (temperature\> 38 ° c), * use of neuromuscular blockers, * use of thoracic drains, generalized edema, * cutaneous lesion in the area of intervention with teds.

Keywords: mechanical ventilation electrical stimulation diaphragm ventilometry physiotherapy
cardiac performance evaluation in children with steroid dependent vs steroid resistant nephrotic syndrome

Conditions: Nephrotic Syndrome

Summary: nephrotic syndrome (ns) is one of the most common pediatric kidney diseases there is an increased incidence of heart disease in patients with primary nephrotic syndrome (pns) compared to the normal population conventional echocardiography is usually utilized to diagnose myocardial dysfunction. tissue doppler imaging is a non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum


Eligibility criteria:
inclusion criteria: * children with primary nephrotic syndrome. * age: 2 - 14 years. * both males and females exclusion criteria: * patients of primary cardiac diseases (e.g., congenital or rheumatic heart disease, cardio- myopathy). patients who refuse to give written informed consent to study
non-surgical treatment of peri-implant mucositis: fmud vs fmud and air-flow master piezon®

Conditions: Peri-implant Mucositis

Summary: the aim of the present study is to evaluate the adjunctive effect of glycine-powder air-polishing (gpap) to full-mouth ultrasonic debridement (fm-ud) in the treatment of peri-implant mucositis, and to determine the predictive role of implant and patient-level variables for disease resolution. both treatments are described in the literature, but few studies are available on their comparison.

52 patients (132 implants) with peri-implant mucositis were included in this randomized parallel arm clinical study. following baseline variables assessment, participants received fm-ud. implants allocated to the test group (n=64) were additionally treated with gpap. clinical outcomes were evaluated at 3 and 12 months following intervention. complete and partial disease resolution were defined as absence of bop (dr1) or \<2 bop+ sites (dr2), respectively.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 years old; * presence of one implant loaded at least one year before; * bleeding on probing and/or suppuration of the peri-implant mucosa; * pain and/or tenderness of the peri-implant mucosa; * good general health conditions. exclusion criteria: * radiographic bone loss ≥ 2mm; * intake of anticoagulants, antiplatelet, antibiotic or cortisone drugs; * inability to perform oral hygiene maneuvers.

Keywords: peri-implant mucosits air polishing device non-surgical treatment
the effect of laughter yoga on the secondary traumatic stress level and psychological well-being of midwives

Conditions: Laughter Yoga

Summary: aim: the aim of this study is to determine the effect of laughter yoga, which includes various relaxing practices, on secondary trauma levels and psychological well-being of midwives. the study was planned as a randomized controlled experimental study. this rct will be administered following the consort 2010 guidelines. material and methods: considering the case losses in the study, it was planned to create a total of 80 midwives, 40 in the intervention group and 40 in the control group. laughter yoga will be practiced in the intervention group. no intervention will be made on the control group. data were collected by using the personal information form, secondary traumatic stress scale, psychological well-being scale.

physiologically, laughter increases blood oxygen saturation, beta endorphin levels increase; it is stated that it has psychological effects such as reducing anxiety, stress, depression and facilitating social communication. laughter yoga is a non-pharmacological therapy. laughter yoga is also used to improve general health, reduce mental symptoms, and improve quality of life. midwives will be randomly assigned to the intervention and control groups, and computer-assisted randomization, one of the fixed probability randomization methods, will be used (https://www.randomizer.org/#randomize). the study will be conducted single-blind. the researcher who will do the laughter yoga and the researcher who will apply the evaluation questionnaires will be different. the researcher who will make the analysis and evaluation will be blind to the groups of midwives. midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. laughter yoga will be practiced by researchers with leadership certification. each session will take an average of 45 minutes. laughter yoga sessions will be held on the web through the "zoom" program. each session will consist of groups of 8 people. before starting the laughter yoga, 5 separate whatsapp groups consisting of 8 people will be established to provide faster and easier communication with the midwives in the intervention group, and communication will be provided by informing and communicating about the sessions. before starting the application, the "zoom" program will be downloaded to the phones or computers of the midwives in the intervention group. "secondary traumatic stress scale" and "psychological well-being scale" will be applied to midwives before and 4-6 weeks after the application. control group: no intervention will be applied to the control group midwives, and the secondary traumatic stress scale" and "psychological well-being scale" will be applied again when they are included in the study and 4-6 weeks later.

Eligibility criteria:
inclusion criteria: * being a midwifery graduate and working actively in the field * volunteering to participate in the research exclusion criteria: * any psychiatric diagnosis

Keywords: laugh yoga secondary trauma psychological well-being
registry on the use of haemocer-plus in the treatment and prevention of post-resectional bleeding

Conditions: Post-resectional Bleeding

Summary: gastrointestinal bleeding is defined as clinical evidence of bleeding manifested by melena, hematochezia that required endoscopic hemostasis. gi bleeding associated to endoscopic procedure is defined as clinical evidence of bleeding and a drop in hemoglobin of ≥ 2g/dl on the day of the procedure (early bleeding) or up to 14 days after the procedure (delayed bleeding).gi bleeding is, nevertheless, a common complication of endoscopic procedures, such as endoscopic mucosal resection (emr) and endoscopic sub mucosal dissection (esd). for example, colorectal esd, which is technically more difficult than gastric or esophageal esd because of the anatomical features of the colon, present an increased risk of delayed bleeding. according to literature, early bleeding occurs on average in 5,3% of endoscopic resections of the whole digestive tract, with bleeding rates per location as follows: esophagus 9.4%, stomach 9.1%, duodenum 3.6%, colon 3.4%. concerning delayed bleeding, it is assessed to complicate 3.1% of endoscopic resection procedures. the bleeding rate in the duodenum is usually the highest (6.3%), followed by colon at (3.6%), stomach (1.5%) and esophagus (0.9%). age, lesion size and piecemeal resection are associated with an increased risk of bleeding. usage of aspirin or nsaids seems to not increase risk of post-polypectomy bleeding, while clopidogrel and warfarin do and should be discontinued in the periprocedural period to prevent the occurrence of post-polypectomy bleeding. direct oral anticoagulants (doac) administration shows similar post-procedural gastrointestinal bleeding risk to anti-vitamin k antagonists (vka) administration in patients undergoing endoscopic procedures.


Eligibility criteria:
inclusion criteria: * patients who had authorized to use and process their personal details for the purpose of research; * patients able to express their consent; * age \>18 years; * endoscopic procedures where haemocer-plus has been used for hemostasis or prevention of bleeding exclusion criteria: * hemostatic therapies other than haemocer-plus * known coagulopathy likely to affect risk of bleeding.
efficacy of baby talcum in prevention of pruritus assosiated with cast

Conditions: Fracture Distal Radius

Summary: this study aims to evaluate the efficacy of baby talcum in prevent pruritus after cast application in orthopaedic patients. the investigators will do a randomized controlled trial in patient with fracture distal end of radius treated conservatively. pruritus score and satisfaction will be monitor along the entire course of cast retention.


Eligibility criteria:
inclusion criteria: * fracture distal end radius treated conservatively exclusion criteria: * open fracture * skin disease and wound under cast area * fracture distal end radius needed surgical management * allergy to baby talcum

Keywords: baby talcum pruritus cast
clinico-demographic features of patients with acne vulgaris

Conditions: Acne Vulgaris

Summary: the global burden of disease study 2010 found that acne vulgaris is the eight most common skin disease, with an estimated global prevalence (for all ages) of 9.38%.(1) furthermore . acne is a chronic inflammatory process that presents with two types of lesions clinically; non-inflammatory (closed and open) and inflammatory lesions (papules ,pustules ,nodules and post inflammatory pigmentary changes).


Eligibility criteria:
inclusion criteria: * patients of both sexes with clinical evident acne vulgaris * any age exclusion criteria: * no exclusion criteria
role of swe-change after tips in the prediction of prognosis after tips

Conditions: Portal Hypertension; Liver Cirrhoses

Summary: the aim of our prospective multicenter study was to investigate the prognostic value of the acute and long-term changes of liver stiffness in patients receiving a transjugular intrahepatic portosystemic shunt (tips).

we included 83 patients receiving tips for prevention of rebleeding, therapy-refractory ascites or both. hemodynamic parameters were assessed before tips and after tips insertion. 16 patients from freiburg underwent te immediately before and after tips. in 67 patients from bonn, swe of liver and spleen, as well as clinical and biochemical parameters were assessed before tips, seven days and six weeks after tips.

Eligibility criteria:
inclusion criteria: * tips insertion and had reliable swe or te measurement exclusion criteria: * contraindication for tips * no reliable swe or te measurement
efficacy and safety of combination therapy for treatment of overactive bladder in male patients with benign prostatic hyperplasia.

Conditions: Overactive Bladder; Benign Prostatic Hyperplasia

Summary: the purpose of this study is to investigate the safety and efficacy of combination therapy involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of oab symptoms in male patients with bph.

mirabegron (myrbetriqtm, astellas pharma inc.) is a drug that is approved by the fda for the treatment of overactive bladder (oab) with symptoms of urinary frequency, urgency and urgency incontinence. multiple studies have shown that this drug also has the potential to improve patient tolerability, compliance and subsequent patient quality of life without inducing unfavourable adverse events commonly associated with antimuscarinic medications. these adverse events include, but are not limited to, dry mouth, constipation, confusion, and acute urinary retention (aur). studies now have shown that mirabegron may also provide an effective treatment option for oab in men with benign prostatic hyperplasia (bph) without inducing the above mentioned adverse events. this study will look at the combination therapy of mirabegron and tamsulosin, versus tamsulosin and placebo alone to prove that this treatment (mirabegron and tamsulosin) is effective for those men who suffer from both overactive bladder along with benign prostatic hyperplasia.

Eligibility criteria:
inclusion criteria: * male patients over the age of 50 * clinical bph on stable dose of alpha-blocker therapy for more than 1 month * oab symptoms (frequency, urgency, nocturia, urgency incontinence) exclusion criteria: * post-void residual (pvr) \> 200ml * active, culture-proven urinary tract infection * acute/chronic prostatitis * previous lower urinary tract malignancy (i.e. bladder, prostate malignancy) * history of cystolithiasis * previous pelvic surgery (i.e. prostatectomy, cystectomy, recent pelvic/endourologic instrumentation including cystoscopy, nephroscopy, ureteral stent insertion, transrectal ultrasound (trus) biopsy) * previous pelvic radiation

Keywords: overactive bladder benign prostatic hyperplasia combination therapy β3-adrenoceptor agonist mirabegron myrbetriq α-adrenoceptor antagonist tamsulosin flomax